TLTFF Theralase Technologies Inc.

$TLTFF I’ve been in and out of this stock for close to ten years. The last time I was long, prior to now, was during the 2024 BTD “carrot and stick debacle”. So I’m keenly aware of regulatory milestone slippage and opaque communication from the company. As grok put quite nicely: “the company has earned a credibility discount because of its historical tendency to promote future regulatory milestones long before demonstrating the operational machinery required to deliver them.” So, NDA slipping a quarter is a known pattern and should certainly put investors on notice. Either regulatory mismanagement or at minimum poor regulatory strategy is a real risk. Just ask your favorite LLM to pull the entire public record history for how the company communicated to investors wrt its handling of BTD.

$TLTFF I recall Matt’s and Roger’s confidence at the outset of the year and how transformative it would be…fast forward 10 months. All cash raise holders significantly under water. Zero news on Ferring cohort 2. NDA pushed to Q4 and a subtle hint “thousands of pages” in the recent promo video that even Q4 could prove too optimistic. The execution risk with micro cap drug developers is almost always the science but with this company it’s the management. It’s run like a private company where unwelcome questions are ignored (or face litigation) and operational holes apparently remain low priorities despite enough cash to make important targeted hires now. Why not just tell us what’s in house and what’s outsourced? How are we to honestly believe in a company that offers complete unwillingness to speak about its regulatory affairs at this crucial moment? And clinical dev planning for future Rutherin trials ? And business development for licensing deals? Shareholders deserve more imo.

$TLTFF my guess is cohort 2 carries much more weight and market interest than NDA. Scant proven BP expertise and an outlier protocol with good not great CR data but a training- learning curve that requires strong licensee/partner commitment means the road to a partnership enabling commercialization is difficult and in question. An international partner is likely the realistic option as N America oncologists require something special to steer them away from their favored immunotherapy protocols. Ferring collab with the potential for exceptional durability data is what’s needed here. Unlike so many longs who assume both ruvidar approval and partnership are within reach I don’t . Complete disinterest and the dirt cheap valuation suggests the market is pricing in major uncertainty, attributing low credibility along with continuous dilution and missed regulatory timelines due to what appears to be a woefully understaffed operation. Just my opinion from cheap seats

$TLTFF Not September any longer, but Q4 hence manipulation by recent institutional raise. Q4 will rock i hope!